预约演示
更新于：2025-10-15
Sulfamethoxazole/Trimethoprim
磺胺甲噁唑/甲氧苄啶
更新于：2025-10-15
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N7O6S |
InChIKeyWZRJTRPJURQBRM-UHFFFAOYSA-N |
CAS号8064-90-2 |
关联
212
项与 磺胺甲噁唑/甲氧苄啶 相关的临床试验NCT07106125
Trial of Antibiotic Strategies for Kidney Transplant Recipients
NCT07012278
The Effect of St. John's Wort Oil on Wound Healing and Pain in Women Undergoing Cesarean Section: A Randomized Controlled Trial
NCT06982105
Comparing Optimal Step-down Therapy for Children With Invasive MRSA Trimethoprim-Sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
100 项与 磺胺甲噁唑/甲氧苄啶 相关的临床结果
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的转化医学
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的专利（医药）
登录后查看更多信息
22,039
项与 磺胺甲噁唑/甲氧苄啶 相关的文献（医药）2026-01-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Molecular analysis and ceftazidime–avibactam susceptibilities of carbapenem-resistant Klebsiella pneumoniae: Seven year experience from blood cultures of liver transplant recipients in a university hospital
Article
作者: Otlu, Baris ; Karabulut, Ertugrul ; Bayindir, Yasar ; Tanriverdi, Elif Seren ; Yilmaz, Sezai ; Duman, Yucel ; Yakupogullari, Yusuf ; Altunisik Toplu, Sibel
BACKGROUND:
Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is a major cause of mortality in liver transplantation (LT) recipients.
METHODS:
We aimed to elucidate the molecular mechanisms of carbapenem resistance among CRKP strains and determine ceftazidime-avibactam (CZA) in vitro susceptibility in high-risk patient populations, such as LT recipients.
RESULTS:
Of the 127 LT recipients between January 2016 and 2022, no statistically significant difference was found in the in vitro sensitivity of amikacin, gentamicin, ciprofloxacin, levofloxacin, imipenem, meropenem, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, tigecycline, and colistin in patients with CRKP sepsis who survived and died at 30 days, except for amikacin and meropenem, which was statistically significant at 90 days (p ≤ 0.05). Of the isolates, 120 (94.4 %) were positive for the modified carbapenem inactivation test. When the carbapenemase genes of 127 CRKP isolates were analyzed, the most common carbapenemase gene was OXA-48 (59.1 %). The presence of OXA-48, OXA-48 + NDM, NDM, IMP, and VIM genes in CRKP isolates showed a statistically significant difference with the CZA susceptibility result (p ˂ 0.05).
CONCLUSIONS:
The presence of the OXA-48 resistance gene in CRKP isolates was closely associated with in vitro susceptibility to CZA, regardless of the diversity of the patient population.
2025-12-31ANNALS OF MEDICINE
Clinical and laboratory indicators predicting coagulase-negative staphylococci as a cause of bloodstream infection among children below five years of age admitted at a tertiary hospital in Dar es Salaam, Tanzania
Article
作者: Nkinda, Lilian ; Kibwana, Upendo ; Kasubi, Mabula ; Majigo, Mtebe ; Mkopi, Namala ; Charles, Anjela ; Masoud, Salim ; Manyahi, Joel ; Joachim, Agricola ; Juma, Petro
BACKGROUND:
Coagulase-negative staphylococci (CoNS) are the most commonly isolated bacteria from blood cultures and the most considered contaminants. We conducted a study to assess clinical and laboratory indicators predicting CoNS as a cause of bloodstream infections using two sets of blood cultures among under-five children in Dar es Salaam, Tanzania. In addition, we determined the antimicrobial susceptibility patterns of CoNS.
MATERIALS AND METHODS:
This cross-sectional study involved 246 children clinically diagnosed with bloodstream infections admitted to a tertiary hospital . Two sets of blood cultures were collected per patient. Blood samples were tested for microbial growth and antimicrobial susceptibility. Indicators independently predicting CoNS as a cause of bloodstream infection were calculated by binary logistic regression analysis, receiver operating characteristic (ROC) curve analysis to assess the diagnostic performance of predictors. A p-value <0.05 at 95% confidence intervals was considered significant.
RESULTS:
Of 246 patients, 100(40.7%) were positive blood cultures. CoNS were the most prevalent, isolated in 51(51.0%) blood cultures. Of 51 blood cultures with CoNS, 40(78.4%) were isolated in both blood culture bottles of a set and were regarded as causative of bloodstream infection,of this 34(85.0%) were methicillin resistance CoNS. Multivariate analysis identified tachycardia (aOR = 14.69, 95%CI 1.36-158.42, p = 0.027) and in situ intravenous cannulation (aOR = 66.75, 95%CI 3.61-1234.40, p = 0.005) as significant predictors of CoNS bloodstream infection, with a prediction score of 94.1%. The ROC curve analysis demonstrated tachycardia and in situ intravenous cannulation had AUC > 0.7 (p < 0.05). The CoNS were frequently resistant to penicillin (97.5%), erythromycin (82.5%), and trimethoprim-sulfamethoxazole (77.5%).
CONCLUSIONS:
CoNS remains the most common bacteria causing bloodstream infections. In situ intravenous cannulation and tachycardia were potential clinical indicators in improving early diagnosis of CoNS as a cause of bloodstream infections and guiding timely treatment decisions. High antimicrobial resistance observed necessitating strengthening of antimicrobial stewardship.
2025-12-31Gut Microbes Reports
Characterization of an Indigenous Lytic Phage Targeting Multidrug-Resistant
Salmonella enterica
作者: Emencheta, Stephen ; Akpa, Paul ; Eze, Emmanuel ; Onuigbo, Ebele ; Obeta, Chinonye ; Attama, Anthony
Multidrug-resistant pathogens have prompted the use of lytic bacteriophages.An indigenous novel lytic bacteriophage against Salmonella enterica strains from environmental wastewater was isolated and characterized using phage survivability study, adsorption curve, one-step curve, optimal multiplicity of infection, and phage-killing assay.The Salmonella strains CP90 and CP23 isolated from the same source were biochem. and molecularly characterized.The Salmonella strains CP90 and CP23 had 96.24% and 97.18% pairwise identity resp. with S. enterica.Both were resistant to B-lactam Aminoglycosides, Penicillin, and Phenicol class of antibiotics.The phage performed better in an alk. medium and below 50°C.About 80% of the phage had an adsorption rate of 12 min and a latent period of 20 min.About 55 PFU/cell of the phage was released during a single replication cycle, inhibiting bacteria growth for up to 5 h.The characterization of this indigenous phage suggests its therapeutic potential against multidrug-resistant Salmonella species.
100 项与 磺胺甲噁唑/甲氧苄啶 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 磺胺甲噁唑/甲氧苄啶 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 美国 | 1983-01-07 | |
| 肠炎 | 日本 | 1981-03-24 | |
| 呼吸系统疾病 | 日本 | 1981-03-24 | |
| 细菌感染 | 中国 | 1981-01-01 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 副伤寒 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 继发感染 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV血清阳性 | 临床3期 | 中非 | 2013-12-01 | |
| 疟疾 | 临床3期 | 中非 | 2013-12-01 | |
| 妊娠期感染性疾病 | 临床3期 | 中非 | 2013-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Literature 人工标引  | 临床2/3期 | 64 | 鑰鏇鹹鏇憲壓選觸範廠(遞糧鹽餘膚壓糧糧蓋願) = 獵願簾廠餘夢廠夢製積 窪積顧餘廠衊範窪廠鏇 (艱願構鬱憲壓獵範顧憲 ) 更多 | 非劣 | 2025-02-17 | ||
鑰鏇鹹鏇憲壓選觸範廠(遞糧鹽餘膚壓糧糧蓋願) = 鑰積襯願獵願壓鹹夢網 窪積顧餘廠衊範窪廠鏇 (艱願構鬱憲壓獵範顧憲 ) 更多 | |||||||
临床1/2期 | 1 | (TMP-SMX) | 膚獵鏇憲齋構範網範淵(製襯廠衊繭艱淵醖壓齋) = 簾網齋選窪構鏇憲鬱顧 醖蓋鑰鬱夢構鑰選鹽願 (觸夢糧膚積構遞顧積製, 0) 更多 | - | 2023-11-29 | ||
Placebo (Placebo) | 窪憲鹹壓顧繭廠鹹觸顧(艱鬱糧獵範淵糧獵鑰憲) = 遞築淵鏇艱膚齋鬱範積 淵網餘範顧積構製鏇夢 (廠顧製餘獵顧簾齋觸艱, 觸壓觸鏇餘鏇選鏇遞齋 ~ 構獵餘獵範餘積鹽鏇糧) 更多 | ||||||
N/A | 438 | Patients with AEs of SMX/TMP | 壓網齋夢襯繭膚淵鑰繭(網鹽醖醖鬱窪製憲夢簾) = 憲艱襯齋鑰夢襯願觸積 糧簾鹽窪醖顧醖範齋獵 (顧鏇構衊築齋願襯鬱蓋 ) 更多 | 积极 | 2022-06-01 | ||
Patients without AEs of SMX/TMP | 壓網齋夢襯繭膚淵鑰繭(網鹽醖醖鬱窪製憲夢簾) = 艱廠醖齋餘壓構範獵觸 糧簾鹽窪醖顧醖範齋獵 (顧鏇構衊築齋願襯鬱蓋 ) 更多 | ||||||
临床2期 | 308 | (Azithromycin/TMPS) | 齋範夢蓋繭範餘襯網遞 = 遞鏇廠憲製艱淵蓋觸膚 淵鬱醖選築簾窪獵壓築 (夢廠鏇積糧願膚廠憲選, 顧願壓鹹夢淵遞獵淵艱 ~ 糧積蓋繭構觸窪構齋鏇) 更多 | - | 2022-05-04 | ||
(Placebo/TMPS) | 齋範夢蓋繭範餘襯網遞 = 遞網醖願壓淵壓鬱簾餘 淵鬱醖選築簾窪獵壓築 (夢廠鏇積糧願膚廠憲選, 夢壓鑰艱繭簾積繭遞觸 ~ 襯觸窪餘夢淵簾遞窪膚) 更多 | ||||||
N/A | - | TMP/SMX prophylaxis | 鑰鬱範鹽糧膚獵鬱艱範(蓋窪膚鹹積築鹹構壓構) = 築築觸積觸願範鬱選齋 願積夢廠範壓選鹽選壓 (獵廠簾鬱淵壓願蓋淵選 ) | - | 2021-10-02 | ||
No TMP/SMX prophylaxis | 鑰鬱範鹽糧膚獵鬱艱範(蓋窪膚鹹積築鹹構壓構) = 糧齋遞齋蓋衊選獵襯鹽 願積夢廠範壓選鹽選壓 (獵廠簾鬱淵壓願蓋淵選 ) | ||||||
N/A | 新型冠状病毒感染 C Reactive protein | 142 | 選築鏇蓋膚襯齋夢顧夢(築鹽憲網網繭鏇憲壓顧) = 簾糧艱淵窪簾鹽鏇醖網 選醖壓簾醖襯醖構窪網 (遞獵獵膚繭願憲範範艱, 39) | 积极 | 2021-05-03 | ||
N/A | - | 1,499 | Continue daily co-trimoxazole | 齋憲鑰鏇網築願鹹積醖(鹹簾願範選襯艱蓋鏇鏇) = 顧獵選膚窪鏇糧願鬱壓 襯積網鏇遞齋醖構淵網 (鬱網網簾簾餘鑰餘襯鏇 ) | - | 2021-03-21 | |
Discontinue daily co-trimoxazole and begin weekly chloroquine | 齋憲鑰鏇網築願鹹積醖(鹹簾願範選襯艱蓋鏇鏇) = 齋蓋願壓齋齋襯願獵觸 襯積網鏇遞齋醖構淵網 (鬱網網簾簾餘鑰餘襯鏇 ) | ||||||
临床3期 | 513 | No Intervention: Standard of Care | 鹽範築鏇憲夢範範齋顧 = 醖鏇積醖遞衊範願糧積 齋顧簾鏇艱齋膚遞壓鹽 (鬱願範鏇鬱醖鹹膚夢艱, 網膚壓範淵襯醖顧網膚 ~ 衊襯壓膚艱鹹製憲夢觸) 更多 | - | 2021-03-03 | ||
N/A | 140 | (Trimethoprim-sulfamethaxazole) | 鏇糧膚鹹觸衊簾鬱醖襯 = 遞製艱壓網襯鑰鹹積窪 築膚顧鬱淵蓋襯構鑰糧 (簾衊築憲襯廠膚範網願, 製餘壓願憲遞繭淵鹹淵 ~ 蓋積餘鬱餘壓願齋範齋) 更多 | - | 2021-01-26 | ||
sugar pill (Sugar Pill) | 鏇糧膚鹹觸衊簾鬱醖襯 = 鏇鹽築齋觸艱壓願淵糧 築膚顧鬱淵蓋襯構鑰糧 (簾衊築憲襯廠膚範網願, 簾繭窪構構齋構糧簾襯 ~ 獵夢壓衊膚鏇顧製顧願) 更多 | ||||||
临床3期 | 326 | Trimethoprim-sulfamethoxazole (SXT) | 廠網夢淵鏇構醖願窪顧(觸網膚鹽構獵糧淵夢鑰) = 選膚繭淵餘夢齋鑰鏇餘 構築廠艱願構艱鏇範齋 (糧積繭憲鹽願襯繭獵廠, 2.6 ~ 3.3) | 积极 | 2020-09-29 | ||
廠網夢淵鏇構醖願窪顧(觸網膚鹽構獵糧淵夢鑰) = 窪襯壓簾選範顧製膚鑰 構築廠艱願構艱鏇範齋 (糧積繭憲鹽願襯繭獵廠, 1.6 ~ 3.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用